ADCs: From Design To Development

Antibody-drug conjugates (ADCs) represent a burgeoning class of targeted therapeutics revolutionizing cancer treatment.  ADCs leverage the specificity of mAb and cytotoxicity of small molecule drugs to deliver efficacious payloads to precise areas. However, this class of drugs has been historically difficult to get through trials.

Explore how an experienced development and manufacturing partner with specialized teams can support running different stages in parallel to facilitate data sharing and clear communication, ultimately taking your ADC from design to development.